These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34178691)

  • 21. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
    Kim KH; Hur JY; Cho J; Ku BM; Koh J; Koh JY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ; Shin EC
    Oncoimmunology; 2020; 9(1):1722023. PubMed ID: 32076579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.
    Llewellyn HP; Arat S; Gao J; Wen J; Xia S; Kalabat D; Oziolor E; Virgen-Slane R; Affolter T; Ji C
    J Hepatol; 2021 Nov; 75(5):1083-1095. PubMed ID: 34242700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
    Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a human glioblastoma model using humanized DRAG mice for immunotherapy.
    Srivastava R; Labani-Motlagh A; Chen A; Yang F; Ansari D; Patel S; Ji H; Trasti S; Dodda M; Patel Y; Zou H; Hu B; Yi G
    bioRxiv; 2023 Feb; ():. PubMed ID: 36824969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
    Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
    [No Abstract]   [Full Text] [Related]  

  • 31. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
    Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
    Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
    Li G; Zhang Z; Cai L; Tang X; Huang J; Yu L; Wang G; Zhong K; Cao Y; Liu C; Wang Y; Tong A; Zhou L
    Oncoimmunology; 2021; 10(1):1983306. PubMed ID: 34595061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.
    Liu J; O'Donnell JS; Yan J; Madore J; Allen S; Smyth MJ; Teng MWL
    Oncoimmunology; 2019; 8(5):e1581530. PubMed ID: 31069141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
    Owen CN; Bai X; Quah T; Lo SN; Allayous C; Callaghan S; Martínez-Vila C; Wallace R; Bhave P; Reijers ILM; Thompson N; Vanella V; Gerard CL; Aspeslagh S; Labianca A; Khattak A; Mandala M; Xu W; Neyns B; Michielin O; Blank CU; Welsh SJ; Haydon A; Sandhu S; Mangana J; McQuade JL; Ascierto PA; Zimmer L; Johnson DB; Arance A; Lorigan P; Lebbé C; Carlino MS; Sullivan RJ; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):917-925. PubMed ID: 33798657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
    Veeranki OL; Tong Z; Mejia A; Verma A; Katkhuda R; Bassett R; Kim TB; Wang J; Lang W; Mino B; Solis L; Kingsley C; Norton W; Tailor R; Wu JY; Krishnan S; Lin SH; Blum M; Hofstetter W; Ajani J; Kopetz S; Maru D
    Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31732509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
    Liu WN; Fong SY; Tan WWS; Tan SY; Liu M; Cheng JY; Lim S; Suteja L; Huang EK; Chan JKY; Iyer NG; Yeong JPS; Lim DW; Chen Q
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM.
    Liu B; Ji Q; Cheng Y; Liu M; Zhang B; Mei Q; Liu D; Zhou S
    J Nanobiotechnology; 2022 Mar; 20(1):161. PubMed ID: 35351131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.